News Archives

BioVaxys Announces Sale Of TAET Software Co.
June 15, 2023

Vancouver, British Columbia, June 13th, 2023 /—-/ BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) is pleased to announce that it has sold TAET Software Co. to [...]

BioVaxys Acquires Clinical Study Management Company and Completes Private Placement
March 16, 2023

VANCOUVER, BC, March 16, 2023 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) today announced that it has acquired TAETSoftware Corp (“TAETCo”), a Vancouver-based clinical [...]

BioVaxys Announces Results from The Ohio State University Pan-Sarbecovirus Animal Study
December 18, 2022

VANCOUVER, BC, December 16th, 2022 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that possibly based on the selected study design, results from The Ohio State [...]

BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
December 1, 2022

VANCOUVER, BC, December 1st, 2022 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) is pleased to announce the successful sterile and bacteria-free test-run production of BVX-0918, the Company’s [...]

BioVaxys Closes First Tranche of Non-Brokered Private Placement
November 28, 2022

Vancouver, British Columbia, November 28, 2022, BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) (“BioVaxys” or the “Company”) announces that it has closed the first tranche (“Tranche 1”) of [...]

BioVaxys Announces Completed Private Placement And Debt Settlement
November 9, 2022

Vancouver, British Columbia, November 9, 2022, BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) (“BioVaxys” or the “Company”) announces that it has completed a non-brokered private placement (the “Private [...]

BioVaxys Announces Debt Settlement
October 27, 2022

Vancouver, British Columbia, October 27, 2022 – BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) (“BioVaxys” or the “Company”) announces that it has agreed to settle an aggregate of [...]

BioVaxys Announces Completed Debt Settlement
October 14, 2022

VANCOUVER, British Columbia, Oct. 14, 2022 /CNW/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC-QB: BVAXF) (“BioVaxys” or the “Company”) announces that, further to its news release dated October 6, [...]

BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps
October 6, 2022

Agreement Includes Right of First Refusal in the US for Ovosicare and Libicare VANCOUVER, BC, October 6th, 2022 /CNW/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today [...]

BioVaxys Further Expands Vaccines Intellectual Property Portfolio
September 28, 2022

VANCOUVER, BC, September 28th, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that in an action that further expands the value of their IP [...]

BioVaxys Announces New Chief Financial Officer
September 8, 2022

VANCOUVER, BC , August 8th, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) (“BioVaxys” or the “Company”) is pleased to announce that Mr. Craig Loverock has joined the Company as Chief Financial [...]

BioVaxys announces completed synthesis of its Pan-Sarbecovirus Vaccine candidate and launch of in vivo animal study
September 6, 2022

VANCOUVER, BC, September 6th, 2022 /CNW/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that Millipore-Sigma, the contract manufacturer for its preclinical viral vaccine program, has [...]

BioVaxys Announces Warrant Extension
August 9, 2022

VANCOUVER, BC, Aug. 9, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB,OTCQB: BVAXF) (“BioVaxys” or the “Company“) announces that it has extended the expiry date of 4,483,689 share purchase [...]

BioVaxys Announces Non-Brokered Private Placement
August 4, 2022

VANCOUVER, British Columbia, Aug. 4, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is pleased to announce a non-brokered private placement (the [...]

BioVaxys Announces Completed Debt Settlement
August 2, 2022

VANCOUVER, B.C., Aug. 2, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) further to its news release dated July 4, 2022, BioVaxys announces [...]

BioVaxys Announces Proposed Debt Settlement
July 5, 2022

VANCOUVER, B.C., July 4, 2022 /CNW/ – BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB,OTCQB: BVAXF) (“BioVaxys” or the “Company”) announces that is proposing to settle an aggregate of approximately $497,000 in [...]

Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development
June 15, 2022

VANCOUVER, BC, June 15th, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that its clinical study collaborator Hospices Civils de Lyon in France (“HCL”) has [...]

Bio-Manufacturing Partner BioElpida Completes Next Phase of BVX-0918 GMP Production for EU Clinical Study
June 8, 2022

VANCOUVER, BC, June 8th, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that its Lyon, France-based bioproduction partner, BioElpida (“BioElpida”), has completed the creation of [...]

BioVaxys and The Ohio State University Progress Pan-Sarbecovirus Vaccine Research Program
June 3, 2022

Pan-Sarbecovirus Vaccines Identified by WHO as a Critical Need VANCOUVER, BC, June 3rd, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”)  announced today that The Ohio State [...]

BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
May 18, 2022

VANCOUVER, BC, May 18th, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that Hospices Civils de Lyon, France (“HCL”) has agreed to serve as a [...]

BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction
April 25, 2022

VANCOUVER, BC, April 25, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB,OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has entered into an agreement with the Deaconess Research Institute [...]

BioVaxys Expands Cancer Vaccine Platform
March 30, 2022

BVX-0922 to Target Colorectal Cancer Under Investigator-Sponsored IND Vancouver, British Columbia, March 30th, 2022 — BioVaxys Technology Corp. (CSE:BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today the expansion of its [...]

Biovaxys Announces Complete Inhibition Of ACE-2 Binding Activity of Hapten-Modified SARS-CoV-2 Protein
February 16, 2022

SUGGESTS SUPERIOR CARDIAC SAFETY COMPARED TO MRNA AND ADENOVIRUS VECTOR VACCINES Vancouver, British Columbia, February 16th, 2022 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”) announced today [...]

Biovaxys Announces Major Research Collaboration With The Ohio State University To Develop Broadly Reactive Pan-Sarbecovirus Vaccine
December 7, 2021

VANCOUVER, BC, December 7th, 2021 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB,OTCQB:BVAXF) (“BioVaxys” or “Company”), a clinical-stage immunotherapy company developing novel approaches to harness T cells to treat cancer and to detect [...]

BioVaxys Co-Founder and Chief Medical Officer David Berd, MD, to Present at World Vaccine & Immunotherapy Congress West Coast 2021
November 17, 2021

VANCOUVER, BC, November 17th, 2021 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB,OTCQB:BVAXF) (“BioVaxys” or “Company”), a clinical-stage immunotherapy company,  announced today that Company Co-Founder and Chief Medical Officer David Berd, MD, will [...]

BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH
November 9, 2021

VANCOUVER, BC, November 9th, 2021 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that results from its in vivo animal research study support the safety and [...]

BioVaxys Further Expands Intellectual Property Portfolio in Global Markets
October 28, 2021

Files Applications for International Patent and Trademark Protection of CoviDTH VANCOUVER, BC, October 28th, 2021 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has [...]

BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine
October 20, 2021

Vancouver, British Columbia, October 20th, 2021 – BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has filed with the United States Patent & Trademark [...]

BioVaxys Announces BVX-0320 Poster Presentation at ISIRV-WHO Virtual Conference
October 8, 2021

SARS-Cov-2 spike protein vaccine induced strong antibody and T cell responses in murine model Vancouver, British Columbia, October 8, 2021 – BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or [...]

BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission
September 28, 2021

VANCOUVER, BC, Sept. 28, 2021 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that it has started its planned in vivo animal [...]

BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins
September 23, 2021

– Potential for superior tolerability to mRNA and Adenovirus Vector vaccines – Production Agreement signed with Millipore-Sigma for SARS-CoV-2 Vaccine Supply VANCOUVER, BC, Sept. 23, 2021 — BioVaxys Technology Corp. (CSE: BIOV) [...]

BioVaxys Engages Life Sciences Public Relations and Market Communications Firm 6 Degrees
September 20, 2021

VANCOUVER, British Columbia, Sept. 20, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”) announced today that it has engaged life sciences and healthcare communications firm 6 [...]

BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone
September 17, 2021

VANCOUVER, British Columbia, Sept. 17, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”), announced today that cancer vaccine manufacturing partner Bio Elpida in Lyon, France, has reached [...]

BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs
September 14, 2021

VANCOUVER, BC, Sept. 14, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”), announced today that global CDMO partner WuXi Biologics, has completed the synthesis of recombinant SARS-CoV-2 [...]

Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID-19 exposure or vaccine administration
September 7, 2021

VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Sept. 7, 2021 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “the Company”) is pleased to [...]

Clinical Trial Affirms CoviDTH Diagnostic Approach To Screen For T Cell-mediated Immune Response To SARS-CoV-2 Is Safe And Effective In Humans
August 3, 2021

YVELISE BARRIOS, MD, PhD, IMMUNOLOGIST AND LEADING EXPERT IN THE CLINICAL USE OF DELAYED TYPE HYPERSENSITIVITY (“DTH”), THE MECHANISM BEHIND CoviDTH, JOINS BIOVAXYS AS SCIENTIFIC ADVISER Vancouver, British Columbia and [...]

Biovaxys Closes Final Tranche of Non-brokered Private Placement
July 29, 2021

Vancouver, British Columbia, July 28th, 2021 BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or the “Company”) is pleased to announce that it has closed the second and final tranche [...]

FDA Provides Necessary Guidance For Biovaxys To Begin Preparation Of IND For Phase I/Ii Clinical Trials Of CoviDTH
July 22, 2021

Vancouver, British Columbia, July 22nd, 2021 BioVaxys Technology Corp. (CSE: BIOV; FRA:5LB; OTCQB: BVAXF) (“BioVaxys”), is pleased to announce today that the US Food and Drug Administration (“FDA”) has provided [...]

BioVaxys Announces Non-Brokered Private Placement
June 29, 2021

Vancouver, British Columbia, June 28th, 2021 BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or the “Company”) is pleased to announce a non-brokered private placement (the “Private Placement”) consisting of [...]

Biovaxys Receives Positive FDA Response For Pre-Ind Review For CoviDTH Clinical Development
June 14, 2021

Vancouver, British Columbia, June 14th, 2021 BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys”), is pleased to announce today that the US Food and Drug Administration (FDA) has reviewed its [...]

BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility to Produce Clinical Supply for Planned Ovarian Cancer Vaccine Study
June 1, 2021

Vancouver, British Columbia and Lyon, France,  June 1st, 2021,   BioVaxys Technology Corp. (CSE:BIOV, FRA:5LB, US OTCQB:BVAXF) (“BioVaxys” or “the Company”) is pleased to announce that its bioproduction partner Bio Elpida [...]

BioVaxys Strengthens Internal Expertise With Appointment of Scientific Advisor for Ovarian Cancer Vaccine Clinical Program and Papilocare Marketing
May 27, 2021

Vancouver, British Columbia. May 24th, 2021,   BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, US OTCQB:BVAXF) (“BioVaxys” or “the Company”) is pleased to announce that Charles J. Dunton, MD, has joined BioVaxys [...]

BioVaxys Announces Appointment of Policy Advisor
May 20, 2021

Vancouver, British Columbia, May 20th 2021 —  BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:BVAXF) (“BioVaxys”), a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic [...]

BioVaxys Announces Uplisting to The OCTQB Venture Market
May 19, 2021

Vancouver, British Columbia, May 19th, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys”), the world leader in haptenized antigen vaccines for antiviral and cancer applications, is pleased to [...]

BioVaxys And BioElpida Sign Definitive Exclusive Agreement to Begin Ovarian Cancer Vaccine Bioproduction
May 3, 2021

Vancouver, British Columbia, April 26th, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: BVAXF) (“BioVaxys” or “Company”) announced today that it has signed the definitive exclusive bioproduction agreement [...]

BioVaxys Broadens Intellectual Property Portfolio – Commercial Trademark Application Filed For CoviDTH® Diagnostic
April 29, 2021

Cancer Vaccine Platform Patent Coverage Expanded To Now Include Over 12 Tumor Types Vancouver, British Columbia, April 29th, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:BVAXF) (“BioVaxys” or “the [...]

Biovaxys Assigned BVAXF By Finra As New Us OTC Trading Symbol
April 21, 2021

Vancouver, British Columbia, April 21st, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:BVAXF) (“BioVaxys”), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced that effective [...]

Biovaxys and The World Ovarian Cancer Coalition Join Forces For May 8th World Ovarian Cancer Day
April 20, 2021

Vancouver, British Columbia, and Toronto, Ontario April 20th, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys”), the world leader in haptenized antigen vaccines for antiviral and cancers applications, [...]

Biovaxys Files FDA Pre-IND Meeting Request And Briefing Package For Covid-T
March 31, 2021

Vancouver, British Columbia, March 31st, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys”), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that [...]

Biovaxys Enters Major Bioproduction Agreement With WuXi Biologics (Hong Kong) Ltd. to Synthesize Proteins for Its Sars-CoV-2 Vaccine and Covid-T™ Immunodiagnostic Programs
March 15, 2021

Vancouver, British Columbia, March 15th, 2021 —  BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys”), the world leader in haptenized protein vaccines for antiviral and cancer applications, announced today that [...]

Biovaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants
March 1, 2021

BVX-0320 and Covid-T to have capability to address UK, Brazilian and South African Virus Variants Vancouver, British Columbia March 1st, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys”), [...]

Biovaxys Announces Broadening Of Share Liquidity With DTCC Full Service Eligibility
March 1, 2021

Vancouver, British Columbia, February 16TH, 2021 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys” or “Company”) is pleased to announce that the company has been approved for DTCC full [...]

Biovaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines
February 10, 2021

USD$900,000 In-Kind Investment by Procare Health into Phase I Clinical Study for BVX-0918A in the EU Co-Development of Vaccines for Cervical Cancer and HPV Right of First Refusal for US [...]

Biovaxys Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program
January 25, 2021

Features Observation of Neutralizing Antibodies to SARS-CoV-2 Advancement of Viral Vaccine Platform and T-cell Diagnostic to Address Emerging SARS-CoV-2 Strains BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) (“BioVaxys” [...]

BioVaxys Provides Viral Vaccine Platform Program Update
November 30, 2020

Titer Analysis Confirms 100% Efficacy at All Higher Dose Levels in Murine Mouse Study; Preclinical Data Supports Expansion of Vaccine Platform Across Range of Viral Diseases Vancouver, British Columbia–(Newsfile Corp. [...]

Biovaxys Announces 96.4 Percent Positive Antibody Immune Response Results From an in Vivo Murine Model Study of its SARS-Cov-2 Vaccine
November 15, 2020

Vancouver, British Columbia, November 10, 2020 —  BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB) (“BioVaxys”) is pleased to announce that results from its preclinical animal study (also known as the “murine [...]

BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity
November 2, 2020

VANCOUVER, BC ― November 2, 2020 ― BioVaxys Technology Corp. CSE: BIOV; “BioVaxys” or “the Company”), a world leader in haptenized protein vaccine research and development, announced today that it [...]

Biovaxys And The Ohio State University Enter Into SARS-CoV-2 Research Collaboration To Study New Vaccine
October 26, 2020

October 26,     2020      Vancouver, British Columbia  BioVaxys Technology Corp. (CSE: BIOV), is pleased to announce that it has entered into a research collaboration with The Ohio State University (“OSU”) for [...]

Appointment of New Director
October 21, 2020

October 16, 2020 – Vancouver, British Columbia – BioVaxys Technology Corp. (formerly Lions Bay Mining Corp.) (“BioVaxys” or the “Company”) (CSE: BIOV) is pleased to announce that David Wang and [...]

BioVaxys Announces Interim Results From Preclinical Study of its SARS-CoV-2 Vaccine
October 14, 2020

October  14th, 2020  Vancouver, British Columbia BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys”) is pleased to announce that interim results from its ongoing preclinical animal study (also known as a “murine [...]

Lions Bay Announces Closing Of Final Tranche Of Non-brokered Private Placement And Provides Update On Completion Of Production And Start Of Dosing In Biovaxys’ Preclincal Study Of SARS-CoV-2 Vaccine
September 4, 2020

September 4, 2020 Vancouver, British Columbia – Lions Bay Mining Corp. (“Lions Bay” or the “Company”) is pleased to announce that it has closed the second and final tranche of [...]

Lions Bay Announces Definitive Agreement for BioVaxys Acquisition and Concurrent Financing
June 4, 2020

Lions Bay Announces Definitive Agreement for BioVaxys Acquisition and Concurrent Financing Vancouver, British Columbia–(Newsfile Corp. – June 4, 2020) – Lions Bay Mining Corp. (CSE: LBM) (the “Company” or “Lions [...]

Lions Bay Mining Announces Update on Acquisition Target BioVaxys Initiating A SARS-CoV-2 Vaccine Study
May 14, 2020

Vancouver, British Columbia–(Newsfile Corp. – May 14, 2020) – Lions Bay Mining Corp. (CSE: LBM) (the “Company” or “Lions Bay“) is pleased to announce that it has been informed that [...]

Thomas Jefferson University and BioVaxys LLC enter into exclusive worldwide license
July 9, 2018

PHILADELPHIA–(BUSINESS WIRE)–Thomas Jefferson University, a Philadelphia-based professional university with a national reputation for transdisciplinary learning and innovation, and BioVaxys LLC, a privately-held, clinical stage biotechnology company, announced today that they [...]